Current Long-Term Pharmacotherapies for the Management of Obesity
- Authors
- Kim, Bo-Yeon; Kang, Seon Mee; Kang, Jee-Hyun; Kim, Kyoung Kon; Kim, Bomtaeck; Kim, Seung Jun; Kim, Yang-Hyun; Kim, Jung-Hwan; Kim, Jae Hyun; Nam, Ga Eun; Park, Ji Yeon; Son, Jang Won; Shin, Hye-Jung; Oh, Tae Jung; Lee, Hyug; Jeon, Hyug Eon-Ju; Chung, Sochung; Hong, Yong Hee; Kim, Chong Hwa
- Issue Date
- 6월-2020
- Publisher
- KOREAN SOC STUDY OBESITY
- Keywords
- Obesity; Orlistat; Lorcaserin; Liraglutide; Naltrexone/bupropion extended-release; Phentermine/topiramate extended-release
- Citation
- JOURNAL OF OBESITY & METABOLIC SYNDROME, v.29, no.2, pp.99 - 109
- Indexed
- SCOPUS
KCI
- Journal Title
- JOURNAL OF OBESITY & METABOLIC SYNDROME
- Volume
- 29
- Number
- 2
- Start Page
- 99
- End Page
- 109
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/55460
- DOI
- 10.7570/jomes20010
- ISSN
- 2508-6235
- Abstract
- Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index >= 25 kg/m(2). Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.